Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Brief Summary: This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. The study will consist of a treatment period (20 weeks) and an observational period (up to 16 weeks). Treatment naive participants will be randomized in a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in a 1:1 ratio to Arms A and C.


Options:
A: Arm Label: Panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal photocoagulation | Arm Label: Bevacizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab | Intervention Type: PROCEDURE; Name: Panretinal photocoagulation; Assigned to Arm(s): Panretinal photocoagulation | Intervention Type: PROCEDURE; Name: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab; Assigned to Arm(s): Bevacizumab + Panretinal Photocoagulation (PRP)
B: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W
C: Arm Label: Arm A: 0.3 mg Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Arm B: 1.5 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Arm Label: Arm C: 6 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): Arm B: 1.5 mg Faricimab, Arm C: 6 mg Faricimab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Arm A: 0.3 mg Ranibizumab
D: Arm Label: ETDRS-PRP group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ETDRS-PRP group | Arm Label: ISQ-RP group; Type: EXPERIMENTAL; Interventions: Procedure: ISQ-RP | Intervention Type: PROCEDURE; Name: ISQ-RP; Assigned to Arm(s): ISQ-RP group | Intervention Type: PROCEDURE; Name: ETDRS-PRP group; Assigned to Arm(s): ETDRS-PRP group

Answer: C